Clinical trial
A Phase I Study of PXD101 in Combination With Azacitidine (5-Aza) for Advanced Hematologic Malignancies
NCT00351975 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of PXD101 in Combination With Azacitidine (5-Aza) for Advanced Hematologic Malignancies
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 30, 2006
- Completion date
- March 31, 2013
- Enrollment
- 56 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
accelerated phase of disease, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21)(q22;q22); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22;q23); mllt3-mll, adult acute promyelocytic leukemia with t(15;17)(q22;q12); pml-rara, atypical chronic myeloid leukemia, bcr-abl1 negative, blastic phase, chronic myelogenous leukemia, bcr-abl1 positive, chronic myelomonocytic leukemia, de novo myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, unclassifiable, philadelphia chromosome negative, bcr-abl1 positive chronic myelogenous leukemia, previously treated myelodysplastic syndrome, primary myelofibrosis, recurrent adult acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, recurrent disease, secondary acute myeloid leukemia, secondary myelodysplastic syndrome